[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:alpha-synuclein":3},{"name":4,"total":5,"recruiting":6,"trials":7},"Alpha-Synuclein",4,3,[8,16,23,29],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06565195","A Clinical Trial of LY3962681 in Healthy Volunteers and in Patients With Parkinson's Disease",[12],"Phase 1","RECRUITING","2026-08-26T02:15:10.362237Z","2026-07-05T05:32:16.759460Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT07589595","A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)",[20],"Phase 2","2026-08-26T02:18:06.247899Z","2026-05-29T15:36:40.200991Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT04477785","PPMI Clinical - Establishing a Deeply Phenotyped PD Cohort",[],"2026-08-26T02:15:43.339060Z","2026-05-13T02:55:06.251770Z",{"nct_id":30,"title":31,"phases":32,"status":33,"updated_at":34,"content_modified":35},"NCT07646652","Alpha-synuclein Education and Disclosure in Individuals With Preclinical and Symptomatic Lewy Body Disease",[],"NOT_YET_RECRUITING","2026-08-26T02:16:47.762107Z","2026-06-16T05:54:07.903276Z"]